- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Sotagliflozin (SAR439954), Glimepiride, Metformin, Placebo
- Drug
- Lead sponsor
- Lexicon Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 954 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 115
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 101 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 63
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- vildagliptin, Glimepiride, LAF237 placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 515 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Type 2 Diabetes
- Interventions
- ITCA 650, glimepiride
- Drug
- Lead sponsor
- Intarcia Therapeutics
- Industry
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Hayward, California
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Linagliptin, Linagliptin Placebo, Glimepiride
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 227 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Peoria, Arizona • Greenbrae, California + 10 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- BI 10773, Glimepiride, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,549 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Hot Springs, Arkansas • Sacramento, California + 20 more
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- liraglutide, placebo, glimepiride
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 40 Years to 70 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- muraglitazar
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1,752 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 108
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 105 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Ranolazine, Placebo, Glimepiride, Diet, Exercise
- Drug · Behavioral
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 431 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 46
- States / cities
- Mesa, Arizona • Tucson, Arizona • Pine Bluff, Arkansas + 39 more
- Conditions
- Pre-diabetes, Type 2 Diabetes
- Interventions
- Exenatide, Sitagliptin, Glimepiride
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 3
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- placebo to match albiglutide, albiglutide, metformin, glimepiride, pioglitazone, placebo to match pioglitazone
- Drug · Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 685 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 321
- States / cities
- Alabaster, Alabama • Birmingham, Alabama • Dothan, Alabama + 257 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- linagliptin, glimepiride, linagliptin placebo, glimepiride placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 6,103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 177
- States / cities
- Athens, Alabama • Birmingham, Alabama • Mobile, Alabama + 139 more
- Conditions
- Diabetes Mellitus
- Interventions
- Pioglitazone, Glimepiride
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 547 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 65
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Huntington Beach, California + 62 more
- Conditions
- Pharmacokinetics
- Interventions
- TAK-875 and Glimepiride
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 68 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Placebo identical to BI 1356 5mg, Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg, BI 1356, Glimepiride
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,560 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 23
- States / cities
- Tempe, Arizona • Chula Vista, California • Los Angeles, California + 19 more
- Conditions
- Type 2 Diabetes
- Interventions
- Intensive insulin, Routine Care
- Drug
- Lead sponsor
- Ohio University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Athens, Ohio
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Glimepiride, Metformin, Pioglitazone, Acarbose, Linagliptin, Sitagliptin, Liraglutide, Insulin Glargine, Exenatide once weekly (QW), Exenatide twice daily (BID)
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 16
- States / cities
- Miami, Florida • New Port Richey, Florida • Orlando, Florida + 12 more
- Conditions
- Diabetes Mellitus, Type 2, Cardiovascular Diseases
- Interventions
- Canagliflozin, Empagliflozin, Dapagliflozin, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-like Peptide-1 (GLP-1) Agonist, Anti-hyperglycemic Agents (AHA), Thiazolidinediones (TZD), Sulfonylureas (SU), Insulin
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- Not listed
- Enrollment
- 714,582 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Titusville, New Jersey
- Conditions
- Cardiovascular Events, Type2 Diabetes, Renal Disease
- Interventions
- SGLT2 inhibitor, DPP-4 inhibitor, GLP-1RA, 2nd generation SU
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 781,430 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes
- Interventions
- Glimepiride, Liraglutide
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 3,474 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Type 2 Diabetes Mellitus, Cardiovascular Diseases
- Interventions
- SU, DPP4, SGLT2i, GLP-1RA, SGLT2i or GLP-1RA, Linagliptin (DPP4), Exenatide (GLP-1RA), Liraglutide (GLP-1RA), Empagliflozin (SGLT2i), Glimepiride (SU), Glipizide (SU), Glimepiride (SU) or Glipizide (SU), SU or DPP4 (excluding saxagliptin and alogliptin), Exenatide (GLP-1RA) or Liraglutide (GLP-1RA)
- Drug
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 241,981 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 6
- States / cities
- Pasadena, California • Pleasanton, California • Honolulu, Hawaii + 3 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Rimonabant, Glimepiride, Metformin
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 508 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Type2 Diabetes Mellitus
- Interventions
- Bexagliflozin, Metformin, Glimepiride, Sitagliptin
- Drug
- Lead sponsor
- Theracos
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Evansville, Indiana
- Conditions
- Diabetes
- Interventions
- Sitagliptin, Glimepiride
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 6,403 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- liraglutide, glimepiride, placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 746 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 102
- States / cities
- Concord, California • Escondido, California • Fullerton, California + 83 more